S&P 500   4,565.43 (-0.05%)
DOW   36,020.93 (+0.19%)
QQQ   387.00 (-0.47%)
AAPL   190.35 (+0.21%)
MSFT   373.84 (-1.34%)
META   322.31 (-1.48%)
GOOGL   131.13 (-1.06%)
AMZN   146.43 (+0.23%)
TSLA   234.20 (-2.45%)
NVDA   463.82 (-0.83%)
NIO   7.05 (-3.03%)
BABA   72.78 (-2.80%)
AMD   118.78 (-1.96%)
T   16.66 (+0.54%)
F   10.39 (+1.27%)
MU   75.23 (-1.17%)
CGC   0.56 (+0.82%)
GE   122.46 (+0.54%)
DIS   92.15 (-0.58%)
AMC   6.85 (+3.01%)
PFE   28.56 (-6.27%)
PYPL   58.42 (+1.41%)
XOM   103.90 (+1.13%)
S&P 500   4,565.43 (-0.05%)
DOW   36,020.93 (+0.19%)
QQQ   387.00 (-0.47%)
AAPL   190.35 (+0.21%)
MSFT   373.84 (-1.34%)
META   322.31 (-1.48%)
GOOGL   131.13 (-1.06%)
AMZN   146.43 (+0.23%)
TSLA   234.20 (-2.45%)
NVDA   463.82 (-0.83%)
NIO   7.05 (-3.03%)
BABA   72.78 (-2.80%)
AMD   118.78 (-1.96%)
T   16.66 (+0.54%)
F   10.39 (+1.27%)
MU   75.23 (-1.17%)
CGC   0.56 (+0.82%)
GE   122.46 (+0.54%)
DIS   92.15 (-0.58%)
AMC   6.85 (+3.01%)
PFE   28.56 (-6.27%)
PYPL   58.42 (+1.41%)
XOM   103.90 (+1.13%)
S&P 500   4,565.43 (-0.05%)
DOW   36,020.93 (+0.19%)
QQQ   387.00 (-0.47%)
AAPL   190.35 (+0.21%)
MSFT   373.84 (-1.34%)
META   322.31 (-1.48%)
GOOGL   131.13 (-1.06%)
AMZN   146.43 (+0.23%)
TSLA   234.20 (-2.45%)
NVDA   463.82 (-0.83%)
NIO   7.05 (-3.03%)
BABA   72.78 (-2.80%)
AMD   118.78 (-1.96%)
T   16.66 (+0.54%)
F   10.39 (+1.27%)
MU   75.23 (-1.17%)
CGC   0.56 (+0.82%)
GE   122.46 (+0.54%)
DIS   92.15 (-0.58%)
AMC   6.85 (+3.01%)
PFE   28.56 (-6.27%)
PYPL   58.42 (+1.41%)
XOM   103.90 (+1.13%)
S&P 500   4,565.43 (-0.05%)
DOW   36,020.93 (+0.19%)
QQQ   387.00 (-0.47%)
AAPL   190.35 (+0.21%)
MSFT   373.84 (-1.34%)
META   322.31 (-1.48%)
GOOGL   131.13 (-1.06%)
AMZN   146.43 (+0.23%)
TSLA   234.20 (-2.45%)
NVDA   463.82 (-0.83%)
NIO   7.05 (-3.03%)
BABA   72.78 (-2.80%)
AMD   118.78 (-1.96%)
T   16.66 (+0.54%)
F   10.39 (+1.27%)
MU   75.23 (-1.17%)
CGC   0.56 (+0.82%)
GE   122.46 (+0.54%)
DIS   92.15 (-0.58%)
AMC   6.85 (+3.01%)
PFE   28.56 (-6.27%)
PYPL   58.42 (+1.41%)
XOM   103.90 (+1.13%)

Augmedix Stock Price, News & Analysis (OTCMKTS:AUGX)

$5.28
+0.13 (+2.52%)
(As of 11/30/2023 ET)
Compare
Today's Range
$5.06
$5.32
50-Day Range
$4.34
$5.72
52-Week Range
$1.01
$5.97
Volume
199,348 shs
Average Volume
443,001 shs
Market Capitalization
$218.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.83

Augmedix MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
29.4% Upside
$6.83 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.27mentions of Augmedix in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.48) to ($0.36) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars


AUGX stock logo

About Augmedix Stock (OTCMKTS:AUGX)

Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Notes that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, a self-service mobile software application. The company enables clinicians to access its applications through mobile devices, such as smartphones or Google Glass. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.

AUGX Stock Price History

AUGX Stock News Headlines

Augmedix, Inc. (AUGX)
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Why Is Augmedix (AUGX) Stock Down 27% Today?
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Are Medical Stocks Lagging Augmedix (AUGX) This Year?
B.Riley Financial Keeps Their Buy Rating on Augmedix (AUGX)
Why Shares of Augmedix Are Climbing on Tuesday
Augmedix's Earnings: A Preview
See More Headlines
Receive AUGX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Augmedix and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/06/2023
Today
11/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Health Information Services
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:AUGX
Fax
N/A
Employees
1,040
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.83
High Stock Price Target
$8.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+29.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

Net Income
$-24,450,000.00
Pretax Margin
-57.23%

Debt

Sales & Book Value

Annual Sales
$40.93 million
Book Value
$0.10 per share

Miscellaneous

Free Float
36,316,000
Market Cap
$218.40 million
Optionable
Not Optionable
Beta
-0.38
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Emmanuel Krakaris (Age 64)
    President, CEO, Secretary & Director
    Comp: $734.33k
  • Mr. Ian Shakil (Age 38)
    Founder, Chief Strategy Officer & Director
  • Ms. Sandra Breber (Age 65)
    Chief Operating Officer
    Comp: $446.05k
  • Mr. Saurav Chatterjee Ph.D. (Age 51)
    Chief Technology Officer
    Comp: $438.05k
  • Mr. Paul Louis Ginocchio (Age 53)
    Chief Financial Officer
  • Todd Holvick
    Head of Legal & Compliance
  • Lia Wallick
    Head of People
  • Dr. Davin Lundquist M.D.
    Chief Medical Officer
  • Mr. Jonathan Hawkins (Age 53)
    Chief Revenue Officer
    Comp: $417.71k














AUGX Stock Analysis - Frequently Asked Questions

Should I buy or sell Augmedix stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Augmedix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUGX shares.
View AUGX analyst ratings
or view top-rated stocks.

What is Augmedix's stock price target for 2024?

3 brokerages have issued 1 year price objectives for Augmedix's shares. Their AUGX share price targets range from $6.00 to $8.00. On average, they anticipate the company's share price to reach $6.83 in the next twelve months. This suggests a possible upside of 29.4% from the stock's current price.
View analysts price targets for AUGX
or view top-rated stocks among Wall Street analysts.

How have AUGX shares performed in 2023?

Augmedix's stock was trading at $1.56 on January 1st, 2023. Since then, AUGX shares have increased by 238.5% and is now trading at $5.28.
View the best growth stocks for 2023 here
.

How were Augmedix's earnings last quarter?

Augmedix, Inc. (OTCMKTS:AUGX) posted its quarterly earnings data on Monday, November, 6th. The company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. The firm earned $11.77 million during the quarter, compared to the consensus estimate of $11.41 million. Augmedix had a negative trailing twelve-month return on equity of 980.09% and a negative net margin of 57.70%.

How do I buy shares of Augmedix?

Shares of AUGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (OTCMKTS:AUGX) was last updated on 12/1/2023 by MarketBeat.com Staff

My Account -